Exxel Pharma, INC.

Aurora, CO · CIK 0002046638 · Biotech · Private

Novel small-molecule therapeutics for neuronal hypersensitivity disorders

exxelpharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$600K
1 Form D · Dec 2024
22 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$600,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1182NEUREXIS THERAPEUTICS, INC.—$605K
1183IQuity Labs, Inc.—$600K
1184Immunaeon Inc.—$250K
1185Exxel Pharma, INC.—$600K
1186Vivid Genomics, Inc.——
1187Ikena Oncology—$43M
1188SHIP OF THESEUS, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 2 related persons
  • Soren MogelsvangDirector · Executive Officer
  • Guy YachinDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.